Trader @KrysAlpine Reports $6,900 Bulenox Payout in Early July 2024
On July 5, 2024, X user @KrysAlpine posted a weekly trading recap stating that $6,900 had been received from Bulenox as the first payout of the month, alongside separate withdrawal requests submitted to two other funded trading firms.
The proof appears in a public X post dated Friday, July 5, 2024, from the account @KrysAlpine. In the same message, the trader confirms receipt of $6,900 from Bulenox as the first payout of July, alongside separate withdrawal requests submitted to two other funded trading firms. The Bulenox amount is described as already received, distinguishing it from the pending requests listed in the same update.
The post is part of a routine end of week recap rather than a promotional thread, which adds to its credibility as a contemporaneous record. The trader frames the Bulenox payment matter of factly, noting that entries were strong during the week while profit taking execution lagged. That self critical tone, paired with a concrete dollar figure and a same week timeline, is consistent with how active funded traders typically document withdrawals on social platforms.
“Received $6,900 from bulenox this week for first payout of July.”— @KrysAlpine on X, July 5, 2024
The proof does not establish several details that readers often want to verify. The post does not specify the Bulenox account size that produced the $6,900 payout, the instruments traded, the holding periods, or the strategy used to reach the withdrawal threshold. It also does not show the internal Bulenox dashboard or a bank transfer confirmation in the message body, although an attached image is referenced. Treat the figure as a trader reported receipt rather than an independently audited statement.
What the post does establish is straightforward and useful. A funded trader operating across multiple firms publicly stated that Bulenox paid $6,900 during the first week of July 2024, and did so in a context where the same author was openly tracking pending payouts elsewhere. For traders evaluating Bulenox alongside competing programs, that kind of side by side disclosure from an active account is a more grounded data point than a standalone marketing testimonial.